SecBot SecBot
SECBOTREPLAY Home › Report › PCRX

PCRX · Pacira BioSciences presented real-world data at AMCP 2026 showing…

Pacira BioSciences · PRESS-RELEASE filed Apr 13, 2026 at 08:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 13, 2026 at 08:00 ET

Pacira BioSciences presented real-world data at AMCP 2026 showing EXPAREL® use in outpatient joint replacement surgeries is associated with lower total healthcare costs and reduced opioid utilization, particularly in patients with low back pain and in teaching hospitals. The findings reinforce EXPAREL's economic value and non-opioid pain management benefits.

  • EXPAREL use in THA was associated with lower total healthcare costs at 3 months ($7,332 vs $8,153) and 6 months ($13,022 vs $15,081) compared to non-LB.
  • In patients with low back pain, EXPAREL showed significantly lower costs at 6 months ($13,614 vs $18,652) and reduced opioid use by 51 MMEs at 6 months.
  • In TKA at teaching hospitals, EXPAREL was linked to statistically significant cost savings at surgical visit, 7 days, and 30 days post-op.
  • A 3-year budget model projected $117,868 in cumulative cost savings per 1 million members with EXPAREL vs ropivacaine.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access